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Gastroesophageal reflux (GER) is commonly associated with respiratory symptoms, either through a vagal bronchoconstrictive
reflex or throughmicroaspiration of gastric contents. No diagnostic test is available, however, to diagnose when respiratory illnesses
are caused by GER and when not, but research in this field has been moving forward. Various biomarkers in different types of
biosamples have been studied in this context. The aim of this review is to summarize the present knowledge in this field. GER
patients with respiratory diseases seem to have a different biochemical profile from similar patients without GER. Inflammatory
biomarkers differ in asthmatics based onGER status, tachykinins are elevated in patients with GER-related cough, and bile acids are
elevated in lung transplant patients withGER.However, studies on these biomarkers are often limited by their small size,methods of
analysis, and case selections. The two pathogenesis mechanisms are associated with different respiratory illnesses and biochemical
profiles. A reliable test to identify GER-induced respiratory disorders needs to be developed. Bronchoalveolar lavage is too invasive
to be of use inmost patients. Exhaled breath condensate samples need further evaluation and standardization.The newly developed
particles in exhaled air measurements remain to be studied further.
1. Introduction
Gastroesophageal reflux (GER) is a growing health problem
in the Western world [1]. It is now generally accepted that
GER is a causative factor for inducing or worsening certain
respiratory symptoms and diseases [2]. GER has also been
shown to be associated with obstructive sleep apnea [3]. The
respiratory diseases that have most frequently been studied
with GER are asthma [4–15] and chronic cough [5, 13, 14, 16–
23], but recently many studies have been published on GER
and lung transplant (LTx) rejection [24–32].
Despite these evident associations, it is difficult to diag-
nose with certainty when respiratory diseases are caused by
GER, or when they cooccur coincidentally.This increases the
need for diagnosticmethods to discriminate between patients
with coincidental cooccurrences and actual causation associ-
ations [33].
Two differentmechanisms are proposed to be responsible
for the majority of GER-induced respiratory symptoms and
diseases. One involves microaspiration of gastric fluids into
the lungs causing irritation and inflammation, and the second
bronchoconstriction caused by a vagal reflex from the distal
esophagus, induced by acidic reflux to the distal esophagus
(Figure 1) [34]. These two mechanisms probably both play
a significant role, but to a different extent in different
conditions.
Serum biomarkers such as gastrin, pepsinogen, and
cleaved fragments of E-cadherin have been studied in patients
suffering from GER. Cleaved fragments of E-cadherin were
found to be significantly increased in serum from GER
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Figure 1: Two theories exist on how gastroesophageal reflux induces respiratory symptoms, called the reflux and reflex theories.
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Figure 2: Summary of biomarkers shown to have an association with gastroesophageal reflux in respiratory illnesses.
patients. As E-cadherin is a junctional protein important
in barrier function in esophageal epithelium, its cleavage
likely explains the increase in junctional permeability in
the esophageal epithelium of these patients [35, 36]. These
studies, however, had no focus on respiratory symptoms.
Clinically it would be of great advantage to have a
diagnostic test that could discriminate between respiratory
symptoms and diseases caused by GER or other causes. To
date, no such generally approved diagnostic test specific to
this condition is available, but research in this field has been
moving forward (Figure 2) [33].The aim of the present paper
is to summarize the findings of studies on various biomarkers
in different biosamples, which have had the objective of
distinguishing between respiratory diseases caused by GER-
and other non-GER-related causes.
2. Methods
When preparing this paper we searched the MEDLINE
database for relevant articles on biomarkers associated with
GER and respiratory diseases, with special emphasis on
biomarkers and biosamples from the distal airways, that is,
bronchoalveolar lavage (BAL) and exhaled breath condensate
(EBC). The MEDLINE database was searched in August–
November 2012 for articles in English. The following search
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Table 1: Biomarkers studied in gastroesophageal reflux with respiratory illnesses.
Biosample Serum Sputum Bronchoalveolar lavage Exhaledair
Exhaled breath
condensate
Studies found 22 34 71 7 16
Studies reviewed 2 11 21 4 8
Biomarkers studied
Eosinophil
cationic
protein
Bile acids Pepsin Bile acids Pepsin FeNO Pepsin
Neurotrophin 3 LLMI IL-4, IL-6 LLMI IL-1, IL-8, IL-15 IL-4, IL-6
BDNF Substance P Neurokinin A IFN-gamma Myeloperoxidase 8-Isoprostane
Nerve growth
factor
Nerve growth
factor
Mast cell
tryptase
Lactate
dehydrogenase Protein carbonyls pH
8-Isoprostane Histamine DPPC SP-A, SP-D Calcium
Prostaglandin
D2 Fibrinogen Elastase pH Magnesium
Eosinophil
cationic protein Chloride
phrases were used: “serum + biomarker + gastroesophageal
+ reflux” (22 articles), “sputum + respiratory + gastroe-
sophageal + reflux” (34 articles), “bronchoalveolar + lavage
+ gastroesophageal + reflux” (71 articles), “exhaled + breath
+ condensate + gastroesophageal + reflux” (16 articles),
“exhaled + nitric + oxide + gastroesophageal + reflux’’ (7 arti-
cles), and “particles + in + exhaled + air + gastroesophageal
+ reflux” (0 articles). Articles were excluded if they contained
no abstract or were not relevant (i.e., not studying biomarkers
in GER with respiratory symptoms). Review articles, case
reports, and letters were also excluded. Animal studies were
excluded. Cytopathological studies were mostly excluded,
except for the exceptional case of the lipid-ladenmacrophage
index (LLMI), usually in bronchoalveolar lavage, a marker
commonly associated with pulmonary aspiration [37–39].
Studies on lung transplant (LTx) patients were included as
GER has a special importance in these patients, causing
inflammation and transplant rejections [40]. First, titles and
abstracts were quickly evaluated with regard to the exclusion
criteria, then a closer evaluation of the remaining articles was
done. One study was moved from the EBC group to the BAL
group [41]. After exclusions, the number of articles identified
in each search was as follows: 1, 9, 21, 7, 4, and 0, respectively.
No duplicate hits were found. A few studies used more than
one biosample and were therefore included in more than one
section in this paper (Table 1).
3. Serum Biomarkers
A specific and sensitive serum biomarker for the detection of
respiratory disorders caused by or linked toGERhas not been
found at present.
In a study by Di Lorenzo et al. [6], patients with GER
and asthma-like symptoms were significantly lower in serum
eosinophil cationic protein (ECP) levels than patients with
diagnosed mild asthma. In fact, those with GER and asthma-
like symptoms had similar levels of ECP as healthy subjects,
while asthmatic patients had three times higher values.
Bronchial hyperresponsiveness was elevated in asthmatic
patients, but was normal in those with GER and asthma-like
symptoms. The authors hypothesize that this might reflect
that those with asthma have mainly eosinophilic inflam-
mation, whereas those with GER have mainly neutrophilic
inflammation in the airways. However, this study was cross-
sectional, and no follow-up studies have been published [6].
In a study by Chaudhuri et al. [17], serum levels of
the neurotrophins nerve growth factor (NGF), brain-derived
neurotrophic factor, and neurotrophin 3 were measured in
81 patients suffering from chronic cough and the levels
compared to those in healthy controls. No significant associ-
ation was found between GER-based chronic cough, defined
by clinical presentation and treatment response, and these
neurotrophins in serum [17].
4. Biomarkers in Sputum
samples contain many biomarkers of inflammation and
infection that are relevant for lung diseases and have been
proposed to be useful for the detection of respiratory dis-
orders caused by or linked to GER. These markers include
bile acids, pepsin, markers for neurogenic inflammation, and
general inflammation.
In a cross-sectional study, bile acids were shown to be
frequently present in induced sputum samples in patients
suffering from cystic fibrosis. The levels of bile acids were
also associated with the degree of lung function impairment
[42]. In another study bile acid levels were shown to be
significantly elevated in induced sputum from patients with
GER and asthma-associated GER symptoms when compared
to asthma patients and healthy controls. Patients with asthma
had a moderate but statistically insignificant elevation of
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bile acids in induced sputum samples, both those with and
without GER [4]. No statistical difference was observed when
bile acid levels in induced sputum from patients with GER-
related chronic cough were compared with sputum samples
from controls [18]. In vitro bile acids have been shown to
induce fibroblast proliferation in airway epithelium, a finding
of unknown importance in humans [4]. There is thus some
evidence that bile acids in sputum indicate GER-induced
respiratory disorder. However, the pathogenesis behind the
association between cough and GER seems to be something
other than aspiration of gastric fluids.
Two studies showed that pepsin concentration in sputum
is not helpful in diagnosing GER-related chronic cough,
and pepsin concentration is frequently detected in sputum
from healthy children [18, 19, 43]. One reason why pepsin
concentration in sputummight not be as useful as amarker of
microaspiration, as originally thought, is that pepsinogen has
been found to be produced in normal human lungs [44, 45].
Lipid laden macrophage index (LLMI), a semiquantitative
evaluation of macrophage lipid content which is considered
to be a biomarker of aspiration, has been studied in the
sputum of GER patients with respiratory symptoms. In a
small study of 22 patients and 15 controls, the LLMI in sputum
was associated with the duration of GER symptoms, but the
levels were not significantly different compared with controls
[46].
In one cross-sectional study, the neurotrophin nerve
growth factor (NGF) levels were measured in sputum from
patients with chronic cough and compared with healthy
controls, but no significant differencewas observed.The same
was true for the subgroup with chronic cough based on GER
[17].
In another study patients with GER and chronic cough
were shown to have 50–100 times more of the tachykinin
substance P in their sputum when compared to GER patients
without chronic cough or healthy subjects [16]. Similarly, a
cross-sectional study of 32 subjects showed a positive asso-
ciation between GER and the tachykinins substance P and
neurokinin A in induced sputum samples, both in asthmatics
and nonasthmatics. A positive correlation between distal
esophageal acid exposure time on 24-hour esophageal pH
monitoring (24 h-pH-m) and tachykinin levels was found.
The presence of these tachykinins suggests airway sensory
nerve activation [5]. These findings support the theory that
certain respiratory symptoms and diseases linked to GER are
caused by a vagally mediated esophageal-tracheobronchial
reflex.
The inflammatory biomarker mast cell tryptase has been
found to be increased in the sputum of GER-associated
chronic cough patients, compared to GER patients without
chronic cough. However, other biomarkers of inflammation
such as prostaglandin D2 and histamine were not signif-
icantly increased in these samples [16]. Another study on
inflammatorymarkers in 20GER patients with cough ormild
asthma found no elevation in fibrinogen levels in induced
sputum, and an elevation in ECP was more associated with
asthma than with GER. The study was, however, limited by
its size [13].
A study on interleukins (IL) and 8-isoprostane in the
sputum of GER and asthma patients showed that IL-4
is similarly elevated in asthmatics, with or without GER.
Conversely, IL-6 and 8-isoprostane were elevated in GER
patients, irrespective of asthma status. Similar findings were
found in BAL samples [7].
In summary, bile acid levels in sputum might be associ-
ated with GER-induced respiratory disorders. There seems
to be a difference in the inflammatory pathways between
asthmatics with or without GER. IL-6 and 8-isoprostane, as
well as substance P and neurokinin A, in induced sputum
seem to predict the presence of GER in subjects both with
or without asthma. Substance P and mast cell tryptase seem
also to predict GER in subjects with chronic cough. Further
studies are needed to clarify these findings.
5. Bronchoalveolar Lavage Biomarkers
A bronchoalveolar lavage (BAL) sample is a biosample col-
lected during a bronchoscopy by infusing saline into a small
segment of the lung and then suctioning up this fluid again
for analysis. The infusion-suction process is then repeated a
few times until an adequate specimen has been obtained [47].
Measurements of bile acids in BAL samples consistently
show that elevated levels of bile acids are a bad prognostic
factor for rejection rates in LTx patients, development of
bronchiolitis obliterans, and survival [26, 32]. There seems
even to be a clear correlation between the time to onset
of bronchiolitis obliterans and levels of bile acids in BAL.
In a study by Blondeau et al., nocturnal GER was found
to be a stronger risk factor for bile acid aspiration in LTx
patients than GER in general, suggesting that nocturnal GER
represents a worse form of GER [26, 28–32].
A study on 96 children with chronic cough, allergic
asthma, and other chronic lung diseases showed no asso-
ciation between GER status, measured by 24 h-pH-m, and
bile acids in BAL [48]. Also, a small study on Wegener’s
granulomatosis patients with subglottic stenosis showed no
significant difference in BAL bile acids; however, since the
study examined a very small number of patients, it may be
a false negative finding [49].
The clinical use of pepsin as a biomarker in BAL samples
has been studied extensively. Many of these studies were on
LTx patients. Observations in these studies, however, were
somewhat different from those on bile acids in BAL samples.
In three of these studies, pepsin in BAL seemed not to
be associated with a clinical decline in LTx patients. One
recent study, however, showed that pepsin was present in
lower quantities in LTx patients who underwent antireflux
surgery than in those who did not and was undetectable in
controls. Those who underwent antireflux surgery also had a
better clinical outcome.This study did not measure bile acids
[25, 28, 29, 31]. Another study on 8 LTx patients undergoing
antireflux surgery showed a similar trend [24].
Two studies on pepsin in BAL samples from chronic
cough patients showed conflicting results. The larger and
more thorough one showed no increase in BAL pepsin
concentration among chronic cough patients compared with
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controls, even though they more often had GER, suggesting
that aspiration is perhaps not the causative mechanism in
GER-associated chronic cough [19, 21]. One study on children
with chronic lung diseases showed that thosewithGERhave a
higher pepsin level in BAL than those without GER, but with
low specificity [48].
Several studies on the clinical use of LLMI inBAL samples
have been carried out. Three of them were on children with
difficult-to-treat respiratory symptoms, often asthma-like,
and one on infants with chronic respiratory diseases. These
studies showed a clear association between GER status and
LLMI [8, 50–52]. In a study on 34 LTx patients, elevated LLMI
levels in BAL samples correlated significantly with abnormal
24 h-pH-m [27]. One study on 33 children with GER-related
respiratory diseases found no increase in LLMI compared
with controls [21]. A large study on 446 children with
respiratory disorders thought to be GER-associated showed
no associations between LLMI and various parameters in
double channel 24 h-pH-m [53]. Therefore, LLMI in BAL
seems to be of limited value in assessing GER-associated
respiratory diseases, except perhaps in LTx patients.
Among 30 children with asthma-like symptoms, those
with GER had higher levels of IL-8, myeloperoxidase, and
elastase in BAL than those without GER [52]. Children
with chronic lung diseases have been shown to have a
positive correlation between IL-8 and protein carbonyl levels
in BAL and proximal reflux events in 24 h-pH-m [48]. In
LTx patients, IL-8 was found to be significantly elevated in
those with elevated bile acids, but not IL-15 [31, 32]. Another
study on 8 LTx patients which underwent antireflux surgery
measured numerous inflammatory markers but found only
that the level of IL-1-beta had decreased whereas the level of
interferon-gammahad increased.However, these results were
most likely confounded by the low number of participants
and the high number of biomarkers studied [24].
Measurements of surfactant in BAL showed that dipalmi-
toylphosphatidylcholine did not differ between children
with reflux esophagitis, cough, and healthy controls [20].
In another study, however, children with GER-associated
chronic respiratory diseases were shown to have prominently
reduced levels of surfactant-protein- (SP-) A and reduced
levels of SP-D, compared with healthy controls [54]. Further
studies are needed to evaluate the potential role of surfactant
proteins as biomarkers to differentiate between chronic res-
piratory diseases with and without GER.
One study on bronchial aspirate in GER patients was
found. Bronchial aspirate differs from BAL in that it does
not introduce any foreign fluid into the lung but aspirates
the pulmonary lining fluid directly. This study showed that
GER patients have higher lactate dehydrogenase levels com-
pared to healthy controls as well as a lower pH. Their lung
function was also decreased compared to healthy controls
[41].
To summarize, bile acids in bronchoalveolar lavage pre-
dict GER-induced transplant rejection in LTx patients. LLMI
seems to be of limited value in assessing GER-associated
respiratory diseases. GER can likely induce inflammation in
the lungs and seems to have a different inflammatory profile
than asthma.
6. Exhaled Breath Condensate Biomarkers
Exhaled breath condensate is a fluid biosample collected by
guiding exhaled air into a condenser system, which cools the
air and forms a condensate of the humidity in the air [55].
A recent study on pepsin levels in EBC samples from idio-
pathic pulmonary fibrosis patients did not show a significant
elevation in pepsin, even though they had more GER symp-
toms on a questionnaire, compared to pulmonary fibrosis
patients of a known cause [56]. The drawbacks of this study
were, however, that it had few participants and used “home-
made” equipment for EBC collection. Carpagnano et al. [7]
showed elevated IL-4 in the EBCof asthmatics, irrespective of
GER status. Conversely, IL-6 and 8-isoprostane were elevated
in GER patients, irrespective of asthma status.These findings
in EBC samples were similar to those in the sputum samples
[7]. Another study found 8-isoprostane to be elevated in
asthmatics, especially if they had comorbid GER, compared
with healthy controls.This elevationwas lowered significantly
with proton pump inhibitor (PPI) treatment among the
asthmatics with GER, but not among the asthmatics without
GER [12].
Asthmatics with GER showed a lower pH in EBC than
asthmaticswithoutGER. PPI treatment seemed to elevate this
low pH to a level similar to other non-GER asthmatics [10,
12]. In a 6-month prospective study on chronic obstructive
pulmonary disease patients, a lower pH in EBC at baseline
did not predict exacerbation frequency during followup.
However, a lower pH in EBC was associated with GER status,
and those with GER did have more exacerbations, suggesting
this might be a false negative finding [57]. The EBC pH in
chronic cough patients with GER was lower than in healthy
controls [22].
Two studies from the same research group on calcium
and magnesium in EBC showed conflicting results. The
former study did not show a direct relationship between
these electrolytes among 66 children with asthma, GER, or
healthy children. The magnesium to calcium ratio, however,
was lower in both children with asthma and those with GER.
The later and larger study found calcium and magnesium to
be elevated among children with GER, and inversely related
to the EBC pH [9, 11]. Another study found levels of chloride
to be lower in the EBC of 5 GER-induced chronic cough
patients compared with 16 healthy controls [22]. As chloride
and a higher pH have antitussive properties, the decrease in
chloride and pH might contribute to the chronic cough in
certain GER patients. HowGER lowers chloride and even pH
in the respiratory tract remains to be studied.
In summary, pulmonary inflammation in GER patients
seems to be induced by different pathways than in asthma
patients, as assessed by exhaled breath condensate. The pH
value of EBC seems to be lowered in GER patients, and
electrolyte disturbances have also been described.
7. Fractional Exhaled Nitric Oxide
Fractional exhaled nitric oxide (FeNO) has frequently been
shown to be elevated in patients with classical asthma, and
more recent evidence has accumulated that it is also a marker
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of eosinophilic inflammation in patients with chronic cough
(eosinophilic bronchitis). Subjects with chronic cough and
GER seem to have significantly lower FeNO than those with
asthma without GER [14]. A cross-sectional study of 20 GER
subjects with cough or asthma, however, did not support this
conclusion, as it was found that asthma rather than GER
caused an elevation in FeNO levels [13].
The presence of GER has been shown to improve
the specificity of FeNO for diagnosing eosinophilic air-
way inflammation. Indeed, FeNO seems only to be of use
among chronic cough patients in diagnosing eosinophilic
airway inflammation when GER is present [23]. In asthmatic
children with GER, FeNO levels were lower than in non-
GER asthmatic children, suggesting that inhalation of gastric
contents may interfere with FeNO production in the airways
[15].
8. Particles in Exhaled Air
Particles in exhaled air (PEx) are formedwhen the respiratory
lining fluid in the small airways erupts as the airways expand,
for example, during inhalation after a deep exhalation [58].
This breathing maneuver is used when PEx are sampled,
using an instrument designed especially for this purpose.The
formed particles follow the exhaled air, the number of PEx is
calculated, and the particles are sampled on a teflon filter by
impaction [59].
No studies on particles in exhaled air (PEx) in GER
were found. The main constituents of PEx are phospholipids
originating from the surfactant. A previous study indicated
increased protonated (H+) adduct formation of the major
phospholipids among smokers, possibly related to alterations
of the pH of the respiratory tract lining fluid (unpublished
data). So far, there are no data on phospholipid alterations of
the surfactant in GER in humans but gastric fluid aspiration
is likely to influence the chemical composition and the pH of
the respiratory tract lining fluid. Whether this also occurs in
the distal airways, reflected by PEx, remains to be elucidated.
9. Conclusions
Numerous studies evaluating biomarkers in GER-related
respiratory conditions have been carried out. This paper
focused mostly on induced sputum, BAL, and EBC samples.
Our conclusion is that GER patients with respiratory diseases
seem to have a different biochemical profile compared to
similar patients without GER. Inflammatory markers differ
in asthmatics based on GER status, tachykinins are elevated
in GER-related cough patients, and bile acids are elevated
in LTx patients with GER. However, the studies on each
biomarker in a specific biosample are often small and few in
number, making definite conclusions on the importance of
these problematic markers.
The studies reviewed here were both on children and
adults. Although these studies seem to be similar in many
ways, some differences can be found. For example, pepsin
seems to be more common in induced sputum in the
pediatric population than the adult population [19, 43].
Children with neurodisability have a high incidence of reflux
aspiration and comprise a specific group ofGERpatients [60].
Therefore, it is important not to draw conclusions about the
adult population from studies on children, and vice versa.
Studies on the lipid laden macrophage index (LLMI)
in BAL samples showed conflicting results. LLMI has been
found to be elevated in pulmonary diseases with no evidence
of aspiration, which also makes it nonspecific [37, 61]. The
usefulness of LLMI in BAL for diagnosing GER seems
therefore to be minimal.
Thepresence of pepsin in biosamples from the respiratory
tract can perhaps not be considered as pathognomonic for
a GER-related pulmonary aspiration. Diagnostic methods
for pepsin are different and recently it was shown that
pepsinogen produced in the lungs could be a confounding
factor. As quite a few studies only measure the presence or
absence of pepsin, further studies should rather assess the
exact magnitude of pepsin in these samples.
The pathogenesis behind the associations of GER with
respiratory diseases seems to be different between different
respiratory diseases. This is reflected in the different bio-
chemical findings. In chronic cough, pepsin and bile acids
are usually not elevated, but tachykinins such as substance
P and neurokinin A are, indicating that a vagally-mediated
bronchoconstrictive reflex is responsible. In contrast, LTx
patients with GER have significantly elevated levels of pepsin
and bile acids, indicating gastric fluid aspiration as a predom-
inant causative factor. This difference in pathogenesis has to
be thought of when planning studies on biomarkers in GER-
associated respiratory diseases.
Reviewing respiratory biomarkers in GER leads to several
perplexities. First and foremost is the wide definition of GER,
which is basically the presence of bothersome symptoms
caused by reflux of gastric contents [2]. GER is diagnosed
based onwidely different questionnaires, sometimes stressing
the importance of sleep-related GER and sometimes not.
Doing 24-hour esophageal pH monitoring (24 h-pH-m) is
sometimes based on only one level of monitoring 5 cm above
the lower esophageal sphincter, but sometimes higher (15 cm)
as well [62]. It has also been pointed out that one negative
24 h-pH-m is not enough to eliminate the possibility of GER.
As many as three nights might be needed. Also, in the
case of EBC, these measurements have shown to have little
reproducibility and are poorly standardized, making their
usefulness currently limited. For the application of EBC to
become more successful, collection methods and biomarker
analyses in EBC samples need to become more standardized.
This standardization would in turn make research collabora-
tions easier, which is crucial for further development of this
method [55, 63].
As the symptoms of GER-induced respiratory disorders
often mimic other common respiratory disorders, a reliable
test to identify GER-induced respiratory disorders needs to
be developed. Such a test should ideally be noninvasive, with a
high positive predictive value, low intraindividual variability,
and change with effective treatment. In this context, the
measurement of a biomarker or a set of biomarkers from
the respiratory tract is of special interest. The BAL samples,
which have been studied the most, are too invasive to be of
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use in populations other than LTx patients. EBC samples are
promising, but need further evaluation and standardization
[55]. The newly developed PEx measurements remain to be
studied further.
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